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Abstract
Background: Antimicrobial resistance has emerged as a major concern in developing countries. The present study
sought to define the pattern of antimicrobial resistance in ICU patients with ventilator-associated pneumonia.
Methods: Between November 2014 and September 2015, we enrolled 220 patients (average age ~ 71 yr) who
were admitted to ICU in a major tertiary hospital in Ho Chi Minh City, Vietnam. Data concerning demographic
characteristics and clinical history were collected from each patient. The Bauer–Kirby disk diffusion method was
used to detect the antimicrobial susceptibility.
Results: Antimicrobial resistance was commonly found in ceftriaxone (88%), ceftazidime (80%), ciprofloxacin (77%),
cefepime (75%), levofloxacin (72%). Overall, the rate of antimicrobial resistance to any drug was 93% (n = 153/164),
with the majority (87%) being resistant to at least 2 drugs. The three commonly isolated microorganisms were
Acinetobacter (n = 75), Klebsiella (n = 39), and Pseudomonas aeruginosa (n = 29). Acinetobacter baumannii were
virtually resistant to ceftazidime, ceftriaxone, piperacilin, imipenem, meropenem, ertapenem, ciprofloxacin and
levofloxacin. High rates (>70%) of ceftriaxone and ceftazidime-resistant Klebsiella were also observed.
Conclusion: These data indicated that critically ill patients on ventilator in Vietnam were at disturbingly high risk
of antimicrobial resistance. The data also imply that these Acinetobacter, Klebsiella, and Pseudomonas aeruginosa
and multidrug resistance pose serious therapeutic problems in ICU patients. A concerted and systematic effort is required
to rapidly identify high risk patients and to reduce the burden of antimicrobial resistance in developing countries.
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Background
Antimicrobial resistance is becoming a global health
challenge that threatens to disengage many medical
achievements of the past century. Since 1940s when
antibiotics were introduced into medicine, the health
and well-being of people worldwide has significantly
improved. However, after many decades of success with
antibiotics, the world is facing a serious threat of bacter-
ial infections and antibiotic resistance which is present
in all countries in the world, contributing to the global
specter of a “post-antimicrobial era”. Apart from resistance
in malaria, other resistance in Klebsiella pneumoniae, E. coli
is also highly prevalence in developing countries. Extensive
drug-resistant tuberculosis (i.e., resistant to at least 4 of the
core anti-tuberculosis drugs) has been found in 105
countries [1]. In the US alone, the annual cost associ-
ated with antimicrobial resistance was estimated to be
$55 billion [2]. In the face of such problems, in September
2016, the United Nations General Assembly convened a
high-level conference to solve the problem of antimicro-
bial resistance [3].
Among healthcare settings of high-risk infection, in-
tensive care unit (ICU) is considered an “epicenter of
infections”. Patients in ICU are vulnerable to infections
because they are exposed to a variety of invasive proce-
dures, including intubation, mechanical ventilation, and
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vascular access. Moreover, some drugs (sedatives, muscle
relaxants) commonly used for ICU patients also increase
the risk for infection. In a multicenter study in Europe,
between 20 and 30% of ICU admissions had nosocomial
infections [4, 5]. Another prospective study in 1265
ICUs from 75 countries found that hospital-acquired
infection was present in ~50% of ICU patients [6]. Taken
together, these studies clearly indicate that ICU patients
are at high-risk for hospital acquired infections, and ICU
is an ideal setting for studying the pattern of antibiotic
resistance.
Although the vast majority of antibiotic resistance burden
is in developing and poor countries, the prevalence and
patterns of resistance have not been well documented for
these countries. Vietnam is a developing country with a
population of 90 million with a heavy demand for health-
care. As far as we know, there have been no studies on the
prevalence of and risk factors for antibiotic resistance
among ICU patients in Vietnam. In this study we sought to
identify patterns of antibiotic resistance in patients admit-
ted to ICU of a major hospital in Vietnam. The finding
from this study can contribute to the development of strat-
egies for a better use of prophylactic and empiric antibiotic
therapy in ICU patients in developing countries.
Methods
Study design and setting
The Study was conducted at Gia Dinh People’s Hospital
(GDPH), Ho Chi Minh City, Vietnam. The Hospital is a
major tertiary teaching hospital of Ho Chi Minh City,
providing care to residents of South Vietnam. The Hospital
has a history of more than 100 years of existence, and
currently has 1500 beds, but it is also constantly over-
loaded with patients. The Hospital has 7 intensive care
units (ICU), including internal medicine, surgery, cor-
onary events, cardiology, stroke, and neonatal care. The
medical ICU (MICU) has 20 beds, with average admission
being 5–7 new patients per day (i.e., about 2500 patients a
years). The surgical ICU (SICU) has 65 beds and admits
about 19,000 patients a year. The stroke ICU has 6 beds
and admits patients from emergency room and stable
medical ICU patients. The present study had been con-
ducted in ICUs between November, 2014 and September,
2015. The study procedure and protocol were approved
by the ethics committee of the University of Medicine and
Pharmacy at Ho Chi Minh City.
We included all ICU patients who gave informed con-
sent to participate in the study. If patient could not give
informed consent, we sought substituted consent from the
patient’s next of kin. Patients on mechanical ventilation
via the tracheostomy or endotracheal tube for more than
48 h at MICU, SICU and stroke ICU of GDPH were
enrolled into the study. Inclusion criteria included chest
radiograph showing new diffuse parenchymal infiltrates.
Patients aged less than 18 years of age or those were
pregnant were not included in the study. The following
patient were also excluded from the study: pneumonia
before mechanical ventilation, acute myocardial infarc-
tion during the first 24 h, and uncontrolled ventricular
arrhythmias.
Data and sample collection
Demographic and clinical data of patients met the inclusion
criteria were collected by a structured questionnaire. Apart
from information concerning the admission to ICU, age,
gender, main cause of admission, medical history, vital signs
and Glasgow coma score were ascertained. Routine
biochemistry tests were performed which included complete
blood count (CBC), blood urea nitrogen, serum creatinine,
blood glucose, and blood electrolytes. Electrocardiogram,
chest X-ray, arterial blood gases and specialized tests were
also performed if there was indication. Patients on
mechanical ventilation were initial setting tidal volume
10 ml per kg, frequency 14 per minute, inspired oxygen
fraction (FIO2) 100%, inspiratory time 1.2 s, assist con-
trol mode and closed suctioning. After 48 h of mechan-
ical ventilation, they were re-evaluated for temperature,
character of sputum, oxygen consumption and use of
antibiotics.
All specimens were collected at the bed-side, and then
transferred to the microbiology laboratory immediately
for inoculation on proper culture media within 2 h. Sample
collection was collected from all patients by bedside
bronchoscopy procedure. A 600 mm length and 50 mm
view depth fiberscope (PortaView LF-TP; Olympus Optical
Co. Ltd., Tokyo, Japan) was attached to a video camera
(Olympus, Tokyo, Japan) and focus with white balance was
manipulated until optimum view was achieved. The
fiberscope was lubricated with sterile xylocaine jelly 2%
(AstraZeneca, Sweden). Midazolam and fentanyl and/or
xusamethonium were used in sedation. The fiberscope
was then introduced until 2 cm above the carina, where
the tube was railroaded into the trachea under vision.
Between 2 and 5 ml of bronchoalveolar lavage (BAL)
fluid was collected. Samples were then transferred to
the microbiology department within 30 min after col-
lection for analysis.
At the microbiology laboratory, the BAL samples were
submitted for Gram stain and culture. Aspiration of
0.5 ml of BAL was diluted 1: 10 with sterile saline 0.9%
(4.5 ml), agitation with Vortex mixer VX 200, 1000 rpm
in 30 s and incubated at 35 °C in 30 min. A 10 μl of
sample diluent 10−1 was inoculated onto 5% blood agar,
chocolate agar haemophilus spp. (CAHI) and MacConKey
Agar media. Plates were incubated at 37 °C in 5% CO2 for
18–24 h. Methods used for confirmation of identification
included examination of colonial morphology and haemo-
lytic characteristics on appropriate agar media, Gram stain,
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rapid tests (catalase, oxidase, coagulase, bile solubility, spot
indole, latex agglutination). A sample was classified as posi-
tive if there were more than 104 cfu per milliliter of BAL
(i.e. ≥ 1 colonies on either medium from the 10−1 dilution).
The detection of antimicrobial susceptibility was per-
formed by standard susceptibility test using the Bauer–
Kirby disk diffusion method. Antimicrobial disc contents
were as follows: amikacin 30 μg, gentamycin 10 μg, ceftri-
axone 30 μg, ceftazidime 30 μg, cefepime 30 μg, cefopera-
zone 75 μg, cefoperazone/sulbactam 75/30 μg, piperacillin/
tazobactam 100/10 μg, ertapenem 10 μg, imipenem 10 μg,
meropenem 10 μg, ciprofloxacin 5 μg, levofloxacin 5 μg,
doxycyllin 30 μg, vancomycin 30 μg and colistin 10 μg. The
classification of in-vitro antimicrobial susceptibility test
results was based on criteria of the Clinical and Laboratory
Standards Institute guidelines (CLSI, 2014). Control strains
were Acinetobacter baumannii ATCC 19606, Pseudomonas
aeruginosa ATCC 27853, Klebsiella pneumoniae ATCC
700603, Escherichia coli ATCC 25922, Staphylococcus
aureus ATCC 25923 (Liofilchem, Italy).
Data analysis
All patients’ data were electronically stored in a rela-
tional database system specifically developed for the
study. The data were then exported into a spreadsheet
for statistical analyses. The prevalence of antimicrobial
resistance was estimated as the proportion of positive re-
sults over the entire study sample. Multi-drug resistance
(MDR) was defined as resistant to at least two anti-
microbial agents. We used a network analysis method to
visualize the co-occurrence of resistance to drugs. In this
method, the line linking between two drugs represents
the number of patients who were resistant to both drugs,
and the size of each node represents the number of pa-
tients who were on a drug. Each line represents at least
5 patients, and the thicker the line the more number of
patients. The graph was constructed for each major or-
ganism. All analyses were conducted using the R statis-
tical software version 3.13 (R Foundation for Statistical
Computing, Vienna, Austria) on the Window platform.
The network graph was constructed using the “igraph”
package.
Results
The study enrolled 220 patients; among whom, 50%
were females. The average age of patients was 71 years
(±16.7 SD). A dominant majority (79%) patients were
from medical ICU, and the remaining 20% were from
surgical ICU (Table 1). In terms of primary diagnosis,
approximately 60% of patients had respiratory failure,
followed by hypertension (37%), diabetes (26%), chronic
kidney disease (16%), heart failure (16%), sepsis shock
(11%). The average APACHE II score was 22 (IQR: 18–
28). The median number of days mechanical ventilation
before enrollment of study and length of stay ICU were
9 (range: 2–83) and 16 (range: 3–135), respectively.
At the time of admission to ICU, about 50% and 45%
patients were being treated with imipenem and levofloxa-
cin, respectively; followed by 30% with cephalosporin 3th
generation, ciprofloxacin (27%), piperacillin – tazobactam
(23%), meropenem (22%). Other antibiotic such as amino-
glycosides, cefoperazone – sulbactam, colistin and vanco-
mycin were also commonly used (Table 2).
At the individual patient level, the prevalence of anti-
microbial resistance was 93% (n = 153/164), with the
majority (87%) being resistant to at least 2 drugs. Drug
resistance was commonly found in ceftriaxone (88%),
ceftazidime (80%), ciprofloxacin (77%), cefepime (75%),
levofloxacin (72%). Resistance to colistin was found in ~2%
(n = 2) patients. Approximately 85% (n = 139) were found
to be multiple-drug resistance (MDR).
Table 1 Clinical characteristics of 220 patients admitted to ICU
Characteristics Statistics
Age (yrs; mean [SD]) 70.7 (16.7)
N (%)
Gender (men) 109 (49.5)
Admission category
Medical ICU 174 (79.1)
Surgical ICU 43 (19.5)
Stroke Unit 3 (1.4)
Primary diagnosis on admission
Respiratory failure 127 (57.7)
Hypertension 80 (36.5)
Diabetes mellitus 57 (25.9)
Chronic kidney disease 36 (16.4)
Cerebral vascular disease 35 (16.0)
Heart failure 34 (15.5)
Sepsis shock 25 (11.4)
Prior medical history
Hypertension 113 (62.4)
Diabetes mellitus 70 (38.6)




No. of days on mechanical ventilation (before enrollment) 9 (6–11.5)
APACHE II score 22 (18–28)
Length of stay ICU (d) 16 (11–25)
*COPD: chronic obstructive pulmonary disease
a: n (%): cancer: 20 [11]; brain hemorrhage: 19 [10]; tuberculosis: 14 [7]; heart
failure: 9 [5]; acute myocardial infarction: 7 [4]; ischemic stroke: 4 [2];
gastrointestinal bleeding, urinary tract infection, prostate enlarge: 2 [1]; others:
84 (46)
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Among patients with ventilator–associated pneumonia,
Acinetobacter emerged as the major causative agent that
accounted for 42% (n = 75) of 177 microorganisms
isolated from patients (Table 3). The next major causative
organism was Klebsiella (22%; n = 39), followed by
pseudomonas aeruginosa (16%; n = 29). There were 13
patients with multiple infections, and the majority of coin-
fection was found in Acinetobacter spp. and Pseudomonas
aruginosa (4.5%; n = 8).
Analysis by major organism and drug (Table 4)
revealed a high rate of antimicrobial resistance among
the three major pathogens (Acinetobacter, Klebsiella, and
Pseudomonas). For example, the rate of Acinetobacter
resistance to ceftazidime, ceftriaxone, cefepime, piperaci-
lin, imipenem, meropenem, ertapenem, ciprofloxacin,
and levofloxacin was greater than 90%. High rate of
resistance to Klebsiella was also noted for ceftriaxone
(83%), ceftazidime (76%), and cefoperazone (73%). Among
the 29 isolates of Pseudomonas, drug resistance was found
in meropenem (86%), imipenem (79%), gentamycin (80%),
ciprofloxacin (80%), and levofloxacin (76%). Even colistin
was found to be resistant to Acinetobacter (1.5%) and
Pseudomonas (3.4%).
The patterns of antimicrobial resistance in Acinetobacter,
Klebsiella, and Pseudomonas formed a network of multiple
drugs as depicted in Fig. 1. In this figure, the degree of
thickness of the connecting lines represents the strength of
association between any two drugs. For instance, Acineto-
bacter was resistant to ceftazidime, ceftriaxone, cefepime,
ertapenem, and ciprofloxacin, and these resistant pathways
formed a complex network. Similar complex networks of
drug resistance were also observed for Klebsiella and
Pseudomonas.
During the follow-up period, 149 patients had died
(incidence rate 68%). The risk of death was associated
with advancing age (P = 0.01) and shorter length of ICU
stay (P = 0.01). On average, the deceased group had a
greater APACHE II score than survivors (23.9 vs 22.1),
but the difference was not statistically significant (P = 0.08).
The risk of mortality among patients with drug resistance
was 67% (103/153) compared with the risk among patients
without drug resistance (45%; 5/11); however, the difference
did not reach a statistical significance (P = 0.19, Fisher’s
exact test). Approximately 91% of those who died in the
drug resistance group were MDR. The risk of mortality
among patients infected with Acinetebacter, P. aeruginosa,
and Klebsiella spp. was 67%, 60%, and 55%, respectively,




Cephalosporin 3th generation 62 (30.1)
Ciprofloxacin 55 (27.0)








Table 3 Distribution of microorganisms isolated from patients
admitted to ICU (N = 177)
Organisms N (%)
Acinetobacter baumannii 55 (31)
Acinetobacter spp 20 (11.3)
Klebsiella pneumoniae 38 (21.5)
Klebsiella spp 1 (0.56)
Pseudomonas aeruginosa 29 (16.3)
Escherichia coli 9 (5.0)
Staphylococcus aureus 9 (5.0)
Burkholderia cepacia 8 (4.5)
Enterobacter cloace 2 (1.1)
Enterobacter spp 1 (0.56)
Stenotrophomonas maltophilia 2 (1.1)
Haemophilus influenzae 1 (0.56)
Serratia marcescens 1 (0.56)
Chryseobacterium indologenes 1 (0.56)
Table 4 Antibiotic resistance of Gram-negative microorganism







Cefoperazone Not done 73.3 Not done
Ceftazidime 93.2 76.3 72.4
Ceftriaxone 95.2 82.7 100
Cefoperazone-sulbactam 4.3 21.0 60.0
Cefepime 93.6 65.7 61.9
Piperacilin - Tazobactam 95.0 64.1 32.1
Imipenem 93.2 25.6 79.3
Meropenem 90.5 20.0 86.2
Ertapenem 100.0 46.4 Not done
Amikacin 77.8 5.1 65.5
Gentamycin 84.1 27.8 80.0
Ciprofloxacin 95.2 52.6 80.0
Levofloxacin 91.5 56.7 75.8
Colistin 1.5 Not done 3.4
Numbers shown are percent of organism-specific total
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but there was no statistically significant difference between
the three organisms.
Discussion
Drug resistance, including antimicrobial resistance, is a
global issue, because it affects people all over the world,
particularly people in developing countries. Based on a
sample of ICU patients in a major hospital in Vietnam,
we have shown that approximately 95% of ventilator-
associated pneumonia patients were resistant to anti-
biotic drugs. More disturbingly, ~85% (n = 139) were
multiple-drug resistant. These results deserve some further
elaboration.
In this study, we found that the distribution of pathogens
was different from previous studies in developing and
developed countries. In most Asian countries, common
pathogens isolated from ICU patients were P. aeruginosa,
Klebsiella spp., E. coli, Enterococcus, and Staphylococcus
aureus [7]. Moreover, the Canadian National Intensive Care
Unit study found that P. aeruginosa, Staphylococcus aureus,
Haemophilus influenzae, Enterococcus spp., Staphylococcus
pneumoniae, and K. pneumoniae are the most common
isolates [8]. However, in our study, the most common
pathogen was Acinetobacter, followed by Klebsiella and P.
aeruginosa. Both Acinetobacter and P. aeruginosa demon-
strated multidrug resistance to several antibiotics.
A striking finding from this study was the degree of
drug resistance among key pathogens. We found a very
high rate of resistance (>70%) among Acinetobacter iso-
lates to most antibiotics, except cefoperazone-sulbactam
(4.3%) and colistin (1.5%). Among Klebsiella isolates,
low resistance was found for amikacin (5.1%), but high
for cefoperazone, ceftazidime, ceftriaxone, cefepime, and
levofloxacin. Resistance to meropenem, imipenem, gen-
tamycin, ciprofloxacin and levofloxacin among P. aerugi-
nosa was consistently over 80%. This is probably due to
the extensive use of third generation of cephalosporins
and quinolone antibiotics in ICU patients.
Previous studies found that the opportunistic pathogens
Acinetobacter spp., mainly A. baumannii, are commonly
found in ICUs. Our study also found that Acinetobacter
was the most common pathogen in ICU patients, and this
finding has significant clinical implications. This Acineto-
bacter spp. has shown a remarkable resistance to many
antibiotic classes. Acinetobacter infection is also associated
with a high risk of mortality, as there are limited treatment
options for this infection. In our study, apart from colistin,
Acinetobacter was resistant to virtually all antibiotics,
Fig. 1 Network graph of multidrug resistance in Acinetobacter (panel
a), Klebsiella (panel b) and Pseudomonas (panel c). The size of each
node proportionally represents the number of patients on a drug.
The line linking between any two antibiotics represents at least 5 patients.
Thus, each line also represents the magnitude of multidrug resistance
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including imipenem (93%), meropenem (90%), ertapenem
(100%), ceftriaxone (95%), ceftazidime (93%), cefepime
(94%), piperacillin (95%), and ciprofloxacin (95%).
Therefore, Acinetobacter is increasingly recognized as
an important cause of hospital-acquired infection [9, 10],
and our finding confirms the significance of this species as
a leading cause of MDR infection in critically ill patients
with ventilator-associated pneumonia.
Klebsiella is considered an opportunistic pathogen,
and Klebsiella infection is commonly found in hospitalized
patients with conditions such as diabetes and chronic pul-
monary obstruction [11]. In human, K. pneumoniae, the
most important species of the genus, was identified as a
pulmonary pathogen more than 100 years ago. While K.
pneumoniae has been declining in the United States [12],
it is still common in China [13], particularly in ventilator-
associated pneumonia patients [14]. In this study, we
found that the pathogen accounted for ~22% of all
infected patients, and the pathogen is also common in
patients with diabetes and pulmonary disorders. In
Southeast Asia, among K. pneumoniae isolates, the re-
sistance rate to ciprofloxacin was 62% in Philippines,
29% in Thailand, and 22% in Singapore [15]. In our
study, the rate of resistance to ciprofloxacin was 53%.
It is not clear why there exists geographic differences
in the rates of resistance between countries, but the
interaction between environmental reservoir and host
variables may be a contributory factor.
In this study P. aeruginosa was the third most common
pathogen in ventilator-associated pneumonia. Previous stud-
ies have also observed that P. aeruginosa is a prominent
cause of pneumonia in hospital setting in Southeast Asia. In
previous studies, ciprofloxacin resistance rates among
Pseudomonas spp. were over 10% in Malaysia and Singapore
[15], which was much lower than our study’s rate (80%).
Although the infection may be due to reservoirs within the
hospital or ICU environment, selective antimicrobial pres-
sure and compromise of the respiratory tract can also be a
risk factor.
Our findings have important clinical implications in
the treatment and management of ICU patients, particu-
larly those with ventilator-associated pneumonia. First,
clinicians should realize that there is a high possibility
that ventilator-associated pneumonia patients are in-
fected with the three common pathogens, and that
multiple drug resistance is a reality. Second, the high
rate of multidrug resistance observed in this study is a
serious concern in the management of ICU patients. It
calls for a more systematic approach to reduce anti-
biotic resistance rates, and minimizing the use of
broad-spectrum antibiotics. Third, in the presence of
multidrug resistance, the development of rapid diag-
nostic test for prompt targeted therapy is an important
priority. There is also a need for implementing a drug
monitoring system that optimizes drug administration
and enable a more personalized approach to treatment.
The present study’s findings nevertheless should be
interpreted within context of strengths and weaknesses.
The study was conducted in a well characterized cohort
of patients, who had been thoroughly followed. We have
been able to analyze a whole spectrum of pathogens and
antibiotic treatments, which allow a relatively compre-
hensive documentation of antimicrobial resistance in
ICU patients. However, we did not have the capacity to
conduct a 16S–rRNA gene sequence analysis to identify
bacterial species, and this is a significant weakness of the
study. Moreover, we did not undertake a phenotypic test
that would provide an insight into the mechanism of
drug resistance. The study was based on a tertiary hospital
and the data were limited to ICU patients; thus the find-
ings may not represent the community acquired infection
in Vietnam. The sample size for the study was modest,
and did not have adequate power to detect smaller effect
sizes or rare incidence. We did not ascertain the specific
causes of infection and comorbidities. We also did not
ascertain all aspects of care that may have resulted in the
prescription of inappropriate antibiotics in our patients.
Conclusion
In this first hospital based study in Vietnam, we ob-
served that ICU-acquired Acinetobacter, Klebsiella and
P. aeruginosa predominate ventilator-associated pneumonia
patients. More disturbingly, ~85% were multiple-drug re-
sistant. The finding here reinforces the view that multidrug
resistance is a global public health issue, and emphasizes
the need to study combined therapies and rational treat-
ment strategies.
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